Literature DB >> 31469696

Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children, Including Children Diagnosed with Asthma.

Edward Goldstein1, Lyn Finelli2, Alissa O'Halloran3, Patrick Liu4, Zeynal Karaca5, Claudia A Steiner5, Cecile Viboud6, Marc Lipsitch1,7.   

Abstract

BACKGROUND: There is uncertainty about the burden of hospitalization associated with respiratory syncytial virus (RSV) and influenza in children, including those with underlying medical conditions.
METHODS: We applied previously developed methodology to Health Care Cost and Utilization Project hospitalization data and additional data related to asthma diagnosis/previous history in hospitalized children to estimate RSV and influenza-associated hospitalization rates in different subpopulations of US children between 2003 and 2010.
RESULTS: The estimated average annual rates (per 100,000 children) of RSV-associated hospitalization with a respiratory cause (ICD-9 codes 460-519) present anywhere in the discharge diagnosis were 2,381 (95% CI(2252,2515)) in children <1 year of age; 710.6 (609.1, 809.2) (1 y old); 395 (327.7, 462.4) (2 y old); 211.3 (154.6, 266.8) (3 y old); 111.1 (62.4, 160.1) (4 y old); 72.3 (29.3, 116.4) (5-6 y of age); 35.6 (9.9,62.2) (7-11 y of age); and 39 (17.5, 60.6) (12-17 y of age). The corresponding rates of influenza-associated hospitalization were lower, ranging from 181 (142.5, 220.3) in <1 year old to 17.9 (11.7, 24.2) in 12-17 years of age. The relative risks for RSV-related hospitalization associated with a prior diagnosis of asthma in age groups <5 y ranged between 3.1 (2.1, 4.7) (<1 y old) and 6.7 (4.2, 11.8) (2 y old; the corresponding risks for influenza-related hospitalization ranged from 2.8 (2.1, 4) (<1y old) to 4.9 (3.8, 6.4) (3 y old).
CONCLUSION: RSV-associated hospitalization rates in young children are high and decline rapidly with age. There are additional risks for both RSV and influenza hospitalization associated with a prior diagnosis of asthma, with the rates of RSV-related hospitalization in the youngest children diagnosed with asthma being particularly high.

Entities:  

Year:  2019        PMID: 31469696      PMCID: PMC6768705          DOI: 10.1097/EDE.0000000000001092

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  34 in total

1.  Impact of respiratory virus infections on persons with chronic underlying conditions.

Authors:  W P Glezen; S B Greenberg; R L Atmar; P A Piedra; R B Couch
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

2.  Estimating deaths due to influenza and respiratory syncytial virus.

Authors:  Nigel J Gay; Nick J Andrews; Caroline L Trotter; W John Edmunds
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

3.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

Authors:  N Sigurs; R Bjarnason; F Sigurbergsson; B Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  The underrecognized burden of influenza in young children.

Authors:  Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 5.  What have we learned from the Tucson Children's Respiratory Study?

Authors:  Fernando D Martinez
Journal:  Paediatr Respir Rev       Date:  2002-09       Impact factor: 2.726

6.  Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.

Authors:  Nele Sigurs; Per M Gustafsson; Ragnar Bjarnason; Fredrik Lundberg; Susanne Schmidt; Fridrik Sigurbergsson; Bengt Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2004-10-29       Impact factor: 21.405

7.  Influenza burden for children with asthma.

Authors:  E Kathryn Miller; Marie R Griffin; Kathryn M Edwards; Geoffrey A Weinberg; Peter G Szilagyi; Mary A Staat; Marika K Iwane; Yuwei Zhu; Caroline B Hall; Gerry Fairbrother; Ranee Seither; Dean Erdman; Pengjun Lu; Katherine A Poehling
Journal:  Pediatrics       Date:  2008-01       Impact factor: 7.124

Review 8.  Clinical assessment of asthma progression in children and adults.

Authors:  Joseph D Spahn; Ronina Covar
Journal:  J Allergy Clin Immunol       Date:  2008-03       Impact factor: 10.793

Review 9.  Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report.

Authors:  L B Bacharier; A Boner; K-H Carlsen; P A Eigenmann; T Frischer; M Götz; P J Helms; J Hunt; A Liu; N Papadopoulos; T Platts-Mills; P Pohunek; F E R Simons; E Valovirta; U Wahn; J Wildhaber
Journal:  Allergy       Date:  2008-01       Impact factor: 13.146

10.  Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City.

Authors:  Donald R Olson; Richard T Heffernan; Marc Paladini; Kevin Konty; Don Weiss; Farzad Mostashari
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

View more
  10 in total

1.  Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination.

Authors:  Michiel van Boven; Anne C Teirlinck; Adam Meijer; Mariëtte Hooiveld; Christiaan H van Dorp; Rachel M Reeves; Harry Campbell; Wim van der Hoek
Journal:  J Infect Dis       Date:  2020-10-07       Impact factor: 5.226

2.  Number needed to immunize to prevent RSV with extended half-life monoclonal antibody.

Authors:  Lyn Finelli; Yoonyoung Choi; Edward Goldstein
Journal:  Vaccine       Date:  2020-06-26       Impact factor: 3.641

3.  Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic.

Authors:  Zachary C Lo; Amy E Sobota
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.170

Review 4.  Vaccines Against Antimicrobial Resistance.

Authors:  Roberto Rosini; Sonia Nicchi; Mariagrazia Pizza; Rino Rappuoli
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

5.  Effects of Air Pollution and Other Environmental Exposures on Estimates of Severe Influenza Illness, Washington, USA.

Authors:  Ranjani Somayaji; Moni B Neradilek; Adam A Szpiro; Kathryn H Lofy; Michael L Jackson; Christopher H Goss; Jeffrey S Duchin; Kathleen M Neuzil; Justin R Ortiz
Journal:  Emerg Infect Dis       Date:  2020-05       Impact factor: 6.883

6.  Burden of respiratory syncytial virus-associated lower respiratory infections in children in Spain from 2012 to 2018.

Authors:  Marco Heppe-Montero; Stefan Walter; Valentín Hernández-Barrera; Ruth Gil-Prieto; Ángel Gil-de-Miguel
Journal:  BMC Infect Dis       Date:  2022-03-31       Impact factor: 3.090

7.  A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.

Authors:  Mina Suh; Naimisha Movva; Lauren C Bylsma; Jon P Fryzek; Christopher B Nelson
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

Review 8.  The Impact of Ambient Environmental Exposures to Microbial Products on Asthma Outcomes from Birth to Childhood.

Authors:  Evin Howard; Vwaire Orhurhu; Lisa Huang; Barbara Guthrie; Wanda Phipatanakul
Journal:  Curr Allergy Asthma Rep       Date:  2019-11-28       Impact factor: 4.919

9.  High Resolution Analysis of Respiratory Syncytial Virus Infection In Vivo.

Authors:  Waleed Aljabr; Stuart Armstrong; Natasha Y Rickett; Georgios Pollakis; Olivier Touzelet; Elaine Cloutman-Green; David A Matthews; Julian A Hiscox
Journal:  Viruses       Date:  2019-10-10       Impact factor: 5.048

10.  Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis.

Authors:  John M McLaughlin; Farid Khan; Heinz-Josef Schmitt; Yasmeen Agosti; Luis Jodar; Eric A F Simões; David L Swerdlow
Journal:  J Infect Dis       Date:  2022-03-15       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.